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TP53, encoding p53, is one of the most famous tumor suppressor genes. The majority of human cancers demonstrate the
inactivation of the p53 pathway. Mutant p53 not only, no longer, functions as a tumor suppressor but can also exert tumor-
promoting eﬀects. The basic function of p53 is to respond to cellular stress. We herein review the recent advances in p53 research
and focus on apoptosis, cell cycle arrest, and senescence in response to stress. We also review the clinical applications of p53-based
therapy for human cancer.
1.Introduction
The TP53 gene, which encodes p53, is one of the most
frequently mutated genes in human cancers. It is reported
that approximately half of all cancers have inactivated p53
[1]. The p53 protein has broad range of biological functions,
including regulation of the cell cycle, apoptosis, senescence,
DNA metabolism, angiogenesis, cellular diﬀerentiation, and
the immune response. Numerous publicationshave reported
various functions of p53 including transcriptional, posttran-
scriptional, and posttranslational roles.
In this paper, we will focus on issues concerning p53 and
application of p53-based cancer therapies. As reviewed by
Vousden and Prives [2], the major functions of p53 are the
regulation of growth arrest and apoptosis.
2.Normal Functionsof p53
Numerous studies have shown p53 to be a transcription
factor that targets many genes and microRNAs in response
to cellar stress. The key role of p53 as a tumor suppressor is
to block cell cycle progression and/or to induce apoptosis, in
response to cellular stresses such as DNA damage. Impaired
p53 activity promotes the accumulation of DNA damage in
cells, which leads to a cancer phenotype. As a transcription
factor, p53 forms a diverse and complex gene regulatory
network. There has been extensive investigation to clarify
the target sequences that p53 recognizes, the p53 response
element (RE), as recently reviewed by Riley et al. [3]p 5 3
has a very wide range of biological activities, so this review
will focus on the role of p53 as a tumor suppressor and its
implications for cancer therapy.
2.1. Human Cancers and p53 Mutations. More than 26,000
somatic mutation data of p53 appear in the international
agency for research on cancer (IARC) TP53 database version
R14 (http://www-p53.iarc.fr/)[ 4].
The frequency of TP53 mutation varies from ∼10%
(hematopoietic malignancies) to 50–70% (ovarian, colorec-
tal,andheadandneckmalignancies)[5].Germlinemutation
of TP53 causes Li-Fraumeni syndrome, which is a familial
cancersyndrome includingbreastcancer,softtissuesarcoma,
and various other types of cancer [6]. Most TP53 mutations
in human cancers result in mutations within the DNA-
binding domain, thus preventing p53 from transcribing its
target genes. However, mutant p53 has not only led to a
loss of normal function of the wild-type protein but also
led to new abilities to promote cancer [5]. The ﬁrst report
of this gain of function by mutant p53 was the observation
that transfection of mutant p53 into p53-null cells enhances
tumor formation in mice [7]. Numerous subsequent studies
have conﬁrmed this ﬁnding [8].
2.2. p53 as a Tumor Suppressor
2.2.1. p53 as a Sensor of DNA Damage. Genetic instability is
one of the most prominent features of malignant tumors.2 Journal of Biomedicine and Biotechnology
There are very sophisticated systems for detecting DNA
damage and repairing the genome. p53 plays an important
rolein such“caretaker”systems. When p53respondstoDNA
damage, it elicits either cell cycle arrest or apoptosis [9].
It was shown in 1991 that induction of wild-type p53
can induce apoptosis in leukemia cells [10]. Mice that have
a speciﬁc p53 mutant lack the ability to induce cell cycle
arrest, but retain the ability to induce apoptosis, allowing
them to eﬃciently suppress oncogene-induced tumors [11],
thus suggesting that the proapoptotic function of p53 may
play a more important role in its antitumor eﬀectsthan in its
induction of cell cycle arrest.
2.2.2. p53 and Apoptosis. Numerous reports have described
the mechanism by which p53 induces apoptosis. As p53
functions mainly as a transcription factor, it is important
to explore the genes regulated by p53 that contribute to the
regulation of apoptosis. Early studies showed that wild-type
p53 can bind the bax gene promoter region and regulate bax
gene transcription [12, 13]. bax is a member of the Bcl-2
family, which forms heterodimers with Bcl-2, inhibiting its
activity [14]. The Bcl-2 protein family plays an important
role in apoptosis and cancer [15, 16]. For example, Bcl-2
controls the release of cytochrome c from the mitochondria,
which activates the apoptotic pathway by activating caspase
9. Caspase 9 then activates executioner caspase 3. Both
caspases play key roles in the apoptotic pathway.
Several human cancers, including colon and stomach
cancer, have altered expression of Bcl-2 [17–19]. However,
the importance of the expression level of Bcl-2 on the
p r o g n o s i so fc a n c e rp a t i e n t si ss t i l lb e i n gi n v e s t i g a t e d .T h e
contribution of bax expression to the prognosis of cancer
patients and the response to therapy is also unclear. In
breast cancer, a study showed that a low level of expression
of bax is associated with a poor prognosis [20], whereas
other reports have shown no correlation between the bax
expression level and prognosis [21]. Further research will
therefore be necessary.
CD95 (also called Fas and Apo-1) is a “death receptor”
indicating its major role in apoptosis. The ﬁrst report of
CD95 showed that an anti-CD95 antibody reduced the
growth of human B-cell xenograft tumors [22]. Since then,
numerous reports have been published about the CD95-
induced signaling pathway in apoptosis. Cytotoxic agents,
such as chemotherapeutic drugs, can induce apoptosis in
drug-sensitive cells. It is therefore important to clarify
which signaling pathway(s) contributes most to apoptosis.
Elucidating this information would be helpful for drug
discovery.
Several reports have indicated the CD95 pathway to
play an important role in apoptosis induced by cytotoxic
agents, and that this system involves the activation of
wild-type p53 [23, 24]. Therefore, the p53 status may
inﬂuence chemosensitivity via CD95 signaling. However, a
recent report indicated that CD95 could promote tumor
growth[25]. Programmed cell death is very complicated and
depends on a variety of factors.
A Bcl-2 subfamily exists which contains only the BH3
domain.SeveralBH3-onlyproteinshavebeenidentiﬁed,and
p53 acts as a transcription factor for PUMA [26, 27]a n d
NOXA [28], which both belong to this class. PUMA is also
a key mediator of the apoptotic pathway induced by p53.
When PUMA is disrupted in colon cancer cells, p53-
induced apoptosis is prevented [27] .P U M Am a yp l a ya
pivotal role in determining cell fate (programmed cell
death versus cell cycle arrest) in response to p53 activation.
A report about PUMA knockout mice [29] showed that
knockout of PUMA recapitulates the apoptotic deﬁciency
observed in p53 knockout mice. PUMA is an essential
mediator for p53-dependent and -independent apoptosis in
vivo [30]. Because evading apoptosis is one of the hallmarks
of cancer [9], PUMA may also play an important role during
carcinogenesis.
Recent reports [31, 32] have shown, however, that in
certain situations, apoptosis can promote carcinogenesis.
Michalak et al. and Labi et al. showed that loss of PUMA
ablated gamma-radiation-induced thymic lymphomagene-
sis. PUMA-deﬁcient hematopoietic stem cells are protected
from gamma-irradiation-induced cell death, which reduces
compensatory proliferation and replication. On the other
hand, wild-type mice experience massive cell death when
they received gamma irradiation, which subsequently led
to repopulation of the region by stem/progenitor cells.
These reports indicate that the homeostasis stem/progenitor
structure of tissue may suppress tumor formation. This
phenomenon will need to be conﬁrmed, but should be
kept in mind when treating patients with strategies such as
chemotherapy and/or radiation.
2.2.3. p53 and Cell Cycle Arrest. The p53 protein suppresses
tumor formation not only by inducing apoptosis but also
by causing cell cycle arrest. Depending on the type of
cellular stress, p53 can induce G1 arrest through activation
of transcription of the cyclin-dependent kinase inhibitor
p21. This process is well known and has been extensively
studied [33]. p53 also regulates the G2/M transition. For
example, p53 can block cell entry into mitosis by inhibition
ofCdc2.Cdc2needstobindtocyclinB1inordertofunction.
Repression of cyclin B1 by p53 also arrests of cells in G2
[34]. However, transient cell cycle may not lead to tumor
eradication, because a cell with oncogenic potential that
cannot be repaired may resume proliferation [2].
Therefore,theothermechanism,cellularsenescence,may
play an important role in p53-mediated tumor suppression.
Cellular senescence is permanent cell cycle arrest. There
are many reports regarding the correlation between tumor
development, p53, and senescence [35, 36]. We will discuss
a few of these factors from the standpoint of cancer therapy.
Oncogenic ras expressed in human and rodent primary cells
results in cellular senescence. This process is due to the
accumulation of p53 and p16. Inactivation of p53 or p16
prevents ras-induced senescence [37]. This report implies
that cellar senescence has an important role in suppressing
tumor development. The inactivation of p53, as is present in
most human cancers, allows cells to evade cellar senescence,
thus resulting in macrolevel tumor development.
p53 also seems to prevent premalignant lesions from
developing into malignant tumors by activating senescenceJournal of Biomedicine and Biotechnology 3
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Figure 1: Vousden and Prives [2] proposed a model of the dual
mechanism of p53 function in tumors. The result of p53 activation
depends on multiple variables. In this model, the p53 response to
low stress results in cell cycle arrest, growth inhibition, DNA repair,
andsoon.Thisresponseenablescellstorestore thedamageinduced
by the cellular stress. But when the cells receive high stress that
cannot be restored, p53 acts as killer that can induce apoptosis
or senescence, preventing proliferation of defective cells. If p53
mistakenly responds as a protector when cells receive a high stress
that cannot be repaired, the cells keep the genetic damage, which
can lead to or contribute to cancer progression (dotted line).
programs [2]. Cellular senescence induced by p53 is impor-
tantnotonlyforcancerpreventionbutalsofortheanticancer
eﬀectinducedbyanywild-typep53introducedinestablished
tumors.
Xue et al. constructed a mouse model oflivercancer with
conditionally regulated endogeneous p53. Reactivation of
endogeneousp53inp53-deﬁcienttumorsresultsincomplete
tumor regressions. Interestingly, the primary response to
p53 was not apoptosis, but the induction of a cellar senes-
cence program. This program triggered an innate immune
response that eliminated the tumor from the host [38].
We have reviewed two important roles of p53 as a tumor
suppressor. Among the various functions of p53, apoptosis
and senescence are the main mechanisms responsible for its
tumor suppression. However, precisely how p53 determines
whether or not the activation of the senescence program or
the apoptosis program occurs still remains to be elucidated.
This question is especially important for the development of
p53-based cancer therapy, including approaches in combi-
nation with conventional chemotherapy. Most conventional
chemotherapeutic agents achieve elimination of cancer cells
by killing them. Therefore, if p53 induces senescence rather
than apoptosis, a conﬂict will emerge. Indeed, it has been
reported that some types of breast cancer are protected from
cytotoxicchemotherapeuticagentsbyendogeneousp53[39].
Therefore, multiple factors, such as the quality and
quantity of cellular stress, the tissue type, and the cellar
microenvironment, determine the fate of the cell. Vousden
and Prives proposed a model wherein the decision between
life and death can be determined by the extent of damage or
the duration of stress [2]. In their model, a low level of stress
which can be repaired elicits a DNArepair/survival response,
while a high level of stress that cannot be repaired induces
an apoptotic or senescence response. This dual nature of
p53, killer and protector, indicates the possibility that p53
may also act as tumor promoter. The antiapoptotic function
of p53 may lead to the survival of damaged cells, which
may increase the possibility for malignant transformation
(Figure 1).
2.3. Applications of p53-Based Cancer Therapy. Because
most, if not all, human cancers harbor altered p53, the
concept of restoration of p53 for cancer therapy is very
attractive. An animal model showed the reactivation of wild-
type p53 to result in eﬃcient tumor regression, including
regression of lymphoma [40, 41] and liver carcinoma [38].
2.3.1. Reactivating Mutant p53. There is class of small
molecules that reactivate the wild-type functions of mutant
p53. PhiKan083 is a carbazole derivative found from in silico
screening of the crystal structure of p53. By binding mutated
p53, PhiKan083 raises the melting temperature of mutated
p53, which results in the reactivation of its function [42].
PRIMA-1 is another small molecule identiﬁed by cell-based
screening which restored sequence-speciﬁc DNA binding
and the active conformation of p53 [43]. CP-31398 is also
a small molecule that can restore the protein folding of
mutated p53 to a more natural conformation that permits
a wild-type function [44].
2.3.2. p53 Stabilization. MDM2 is an E3 ubiquitin ligase
which controls p53 degradation. Many tumors overexpress
MDM2 [45], even tumors without p53 mutations [46]. Tar-
getingMDM2for p53stabilizationseems tobepromising, so
many reports on targeting MDM2 or the MDM2-p53 have
been published.
For example, the nutlins are cis-imidazoline compounds
that act as antagonists of the MDM2-p53 interaction.
Analysis of the crystal structure showed that nutlin binds in
the pocket of MDM2 to prevent the p53-MDM2 interaction.
Nutlin can activate the p53 pathway, thereby inducing cancer
cells and xenograft tumors in mice to undergo cell cycle
arrest, apoptosis, and growth inhibition [47].
MI-219 is another small molecule that inhibits the
MDM2-p53 interaction. MI-219 also activates the p53
pathway in cells with wild-type p53. Apoptosis and cell cycle
arrest were observed in xenograft tumors which resulted in
tumor regression [48].
However, MDM2 inhibition and p53 activation in nor-
mal tissue may be harmful. Ringshausen et al. showed that
p53 is spontaneously activated in many tissues in MDM2-
deﬁcientmice. Moreover, p53triggered fatal pathologiesthat
includedtheablationofclassically radiosensitive tissues[49].
2.3.3. Other Classes of Drugs for p53 Stabilization. Tenovin
was found by a cell-based drug screen to activate p53.4 Journal of Biomedicine and Biotechnology
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Figure 2: Strategies for p53 stabilization and reactivating mutant
p53.
Tenovin acts as an inhibitor of the protein-deacetylating
activities of SirT1 and SirT2. The intraperitoneal admin-
istration of tenovin-6 has been demonstrated to induce a
regression of xenograft tumors in a mouse mode [50].
Issaeva et al. screened a chemical library and found the
small molecule RITA (reactivation of p53 and induction
of tumor cell apoptosis), which binds to p53 and inhibits
the p53-MDM2 interaction both in vitro and in vivo.R I T A
induced apoptosis in various cancer cells that retained wild
type p53 [51]. They also found that the p53 released from
MDM2 by RITA promotes p21 and hnRNP K (a p53 cofac-
tor), thus implying that p21 plays a major role in regulating
the cancer cell fate after p53 reactivation [52]( Figure 2).
2.4. p53 Inhibition for Cancer Therapy. The inhibition of
p53can protectnormal cells duringgenotoxicchemotherapy
or radiation therapy. The side eﬀects of genotoxic therapy
for cancer are largely caused by p53-mediated apoptosis.
The small moleculepiﬁthrin-alpha can blockp53-dependent
transcriptional activity and protect mice from the lethal side
eﬀects associated with anticancer treatment [53]. If we can
avoid dose-limiting genotoxic stress to normal cells during
chemotherapy or radiotherapy for cancer, it will thus allow a
higher dose to be used for patients who are not suﬃciently
responsive to conventional chemotherapy.
2.5. p53 Gene Therapy. T h eﬁ r s tp 5 3 - b a s e dg e n et h e r a p yw a s
reportedin1996.Aretroviralvectorcontainingthewild-type
p53geneunderthecontrolofan actin promoterwas injected
directly into tumors of nonsmall cell lung cancer patients
[54]. After development of a replication-defective recombi-
nantp53virus(Ad5CMV-p53)[55],many clinicaltrials have
been performed, including one in esophageal cancerpatients
[56]. A few trials reached phase III, but ﬁnal approval from
the FDA has not yet been granted [57]. Recently, p53-based
gene therapy has been developing in China [58].
2.6. p53-Based Immunotherapy. Tumor-associated antigen-
speciﬁc cytotoxic T lymphocyte can mediate immune
response of host against cancer in vivo [59]. P53 protein,
especially targeting missense mutation of p53, can be
candidate of tumor antigen [60]. Some cancer patients
have antibodies against p53 [61], the frequency and clinical
signiﬁcance are still under debate [62].
Speetjens et al. reported clinical trials of a p53-speciﬁc
synthetic long peptide (p53-SLP) vaccine for metastatic
colorectal cancer patients [63]. Ten patients were vaccinated
with p53-SLP in a Phase I and Phase II trial. Toxicity was
tolerable, and p53-speciﬁc immune response was detected
in 9 of 10 patients. P53-speciﬁc T-cell reactivity persisted
more than 6 month in 6 of 9 patients. Although the trial was
Phase I/II, the clinical beneﬁt may be hard to obtain because
most patients had T-helper cells that lacked key cytokines
[64]. Preclinical phase I/ II trial of INGN-225 (Introgen), a
p53-modiﬁed adenovirus-induced dendritic cell vaccine for
small cell lung cancer (SCLC) patients, has been reported
[65]. INGN-225 was well tolerated and induced p53-speciﬁc
immune response in 18/43 (41.8%) patients and sensitized
SCLC to subsequent chemotherapy.
3.Conclusion
In this paper, we focused on the functions of p53 and clinical
applications targeting p53 for cancer therapy. However,
despite recent advances in the research on p53’s cytoplasmic
function,itappearsthatvariousrolesremaintobeelucidated
other than its function as a nuclear factor [66]. p53 has been
reportedtoinduceapoptosisindependentofitstranscription
of genes as early as 1994 [67]. Surprisingly, activated p53
can induce apoptosis in the cytoplasm by a bax-dependent
mechanism [68].
These reports indicate that cytoplasmic p53 can activate
a transcription-independent apoptotic program. The next
generation of p53-based cancer therapeutic approaches
should therefore be developed to take advantage of this
cytosolic function. This may be safer than regulating the
transcription modulation of wild-type p53, which can
induce both prosurvival and proapoptotic eﬀects in tumor
cells, as discussed above.
Recentreportshaveshowedthatp53regulatestheprocess
of self-renewal of neural stem cells [69]a n dh e m a t o p o i e t i c
stem cells [70]. The cancer stem model insists that tumors
are maintained by a small population of cancer stem cells
that can divide both symmetrically and asymmetrically. Loss
of p53 promotes acute myeloid leukemia by aberrant self-
renewal [71].
Mammary stem cells with the targeted mutation of p53
have been reported to show the same properties as cancer
stem cells. The reactivation of p53 restored the asymmetric
cell division of cancer stem cells and induced tumor growth
inhibition [72]. As a result, further investigation of the link
betweenthep53functionandcancerstemcellsmaytherefore
be one of the most important research ﬁelds for uncovering
new paradigms in cancer therapy.
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